Why the study?
Does candesartan compared to enalapril reduce ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy?
Does candesartan compared to enalapril reduce ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy?
Both candesartan and enalapril induce a moderate reduction in an echoreflectivity index of myocardial fibrosis in hypertensive patients with LVH, with no significant difference between the two agents.
Answers are grounded in this paper and cite their sources.
Both agents reduce myocardial fibrosis markers similarly in hypertensive LVH; confirms comparable antifibrotic effects of ARB and ACEI.
OBJECTIVE: To compare the effects of the angiotensin II receptor antagonist candesartan with the angiotensin-converting enzyme inhibitor enalapril on myocardial fibrosis evaluated by echoreflectivity analysis. METHODS: Hypertensive patients (n = 196) with echocardigraphically documented left ventricular hypertrophy were randomized to candesartan 8-16 mg/day (n = 91) or enalapril 10-20 mg/day (n = 105) with possible addition of hydrochlorothiazide (12.5-25 mg/day) for 48 weeks. Echoreflectivity analysis was performed on ultrasound two-dimensional tracings of the midapex septum with a specifically designed and validated software. Colour histograms were obtained; the primary outcome variable was the treatment-related change in histogram width (broadband), previously shown to correlate with collagen volume on endomyocardial biopsy; changes in mean colour scale were secondary outcome variable. RESULTS: Echoreflectivity analysis was feasible in 84 patients (48 candesartan, 36 enalapril). Broadband decreased significantly in the candesartan (-8.0 colour levels) and in the enalapril group (-12.9 colour levels) with no significant difference between treatments (P = 0.409); no significant changes occurred in mean colour scale. Patients under monotherapy (n = 46) showed similar trends as the larger intention to treat cohort, without significant difference between treatments. CONCLUSION: In hypertensive patients with left ventricular hypertrophy, both candesartan and enalapril induce a moderate but statistically significant reduction in an echoreflectivity index of myocardial fibrosis.
No takes yet. Share an insight, caveat, or question.
Ciulla et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: